Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy B Rubis

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C. : 2002)|April 14, 2026
Tetanus Surveillance - United States, 2009-2023Michelle M Hughes, Avnika B Amin, Amy B Rubis
The New England Journal of Medicine|January 7, 2026
Serogroup Switching in <i>Neisseria meningitidis</i> with Dual Antibiotic ResistanceRebecca L Howie, Shalabh Sharma, Jennifer L Kyle, et al.
MMWR. Morbidity and Mortality Weekly Report|June 15, 2023
Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV - United States, 2022Amy B Rubis, Rebecca L Howie, Daya Marasini, et al.
MMWR. Morbidity and Mortality Weekly Report|February 8, 2024
Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance - United States, 2024Isha Berry, Amy B Rubis, Rebecca L Howie, et al.
Open Forum Infectious Diseases|December 27, 2023
Risk Factors for Serogroup B Meningococcal Disease Among College StudentsLauren M Weil, Samuel J Crowe, Amy B Rubis, et al.
Plos One|June 9, 2025
Enhanced Surveillance for Meningococcal Disease-United States, 2015-2019Amy B Rubis, Daya Marasini, Rebecca Howie, et al.
Open Forum Infectious Diseases|November 25, 2024
Impact of the US Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccination Program on Preventing Pertussis in Infants 2 to <6 Months of Age: A Case-Control EvaluationTami H Skoff, Amy B Rubis, Pam Daily Kirley, et al.
Plos One|December 4, 2024
SARS-CoV-2 coinfections among pertussis cases identified through the Enhanced Pertussis Surveillance system in the United States, January 2020-February 2023Isha Berry, Matthew Cole, Benjamin Silk, et al.
Open Forum Infectious Diseases|April 26, 2024
Differences in Pertussis Incidence by Race and Ethnicity in the United States, 2010-2017Jaymin C Patel, Matthew Cole, Amy B Rubis, et al.
Plos One|May 18, 2023
High post-exposure prophylaxis (PEP) uptake among household contacts of pertussis patients enrolled in a PEP effectiveness evaluation - United States, 2015-2017Lucy A McNamara, Amy B Rubis, Lucia Pawloski, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C. : 2002)|April 14, 2026
Tetanus Surveillance - United States, 2009-2023Michelle M Hughes, Avnika B Amin, Amy B Rubis
The New England Journal of Medicine|January 7, 2026
Serogroup Switching in <i>Neisseria meningitidis</i> with Dual Antibiotic ResistanceRebecca L Howie, Shalabh Sharma, Jennifer L Kyle, et al.
MMWR. Morbidity and Mortality Weekly Report|June 15, 2023
Notes from the Field: Increase in Meningococcal Disease Among Persons with HIV - United States, 2022Amy B Rubis, Rebecca L Howie, Daya Marasini, et al.
MMWR. Morbidity and Mortality Weekly Report|February 8, 2024
Selection of Antibiotics as Prophylaxis for Close Contacts of Patients with Meningococcal Disease in Areas with Ciprofloxacin Resistance - United States, 2024Isha Berry, Amy B Rubis, Rebecca L Howie, et al.
Open Forum Infectious Diseases|December 27, 2023
Risk Factors for Serogroup B Meningococcal Disease Among College StudentsLauren M Weil, Samuel J Crowe, Amy B Rubis, et al.
Plos One|June 9, 2025
Enhanced Surveillance for Meningococcal Disease-United States, 2015-2019Amy B Rubis, Daya Marasini, Rebecca Howie, et al.
Open Forum Infectious Diseases|November 25, 2024
Impact of the US Maternal Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccination Program on Preventing Pertussis in Infants 2 to <6 Months of Age: A Case-Control EvaluationTami H Skoff, Amy B Rubis, Pam Daily Kirley, et al.
Plos One|December 4, 2024
SARS-CoV-2 coinfections among pertussis cases identified through the Enhanced Pertussis Surveillance system in the United States, January 2020-February 2023Isha Berry, Matthew Cole, Benjamin Silk, et al.
Open Forum Infectious Diseases|April 26, 2024
Differences in Pertussis Incidence by Race and Ethnicity in the United States, 2010-2017Jaymin C Patel, Matthew Cole, Amy B Rubis, et al.
Plos One|May 18, 2023
High post-exposure prophylaxis (PEP) uptake among household contacts of pertussis patients enrolled in a PEP effectiveness evaluation - United States, 2015-2017Lucy A McNamara, Amy B Rubis, Lucia Pawloski, et al.
Pageof 2